A2 Katsausartikkeli tieteellisessä aikausilehdessä
An investigation of antihypertensive class, dementia, and cognitive decline : A meta-analysis (2020)
Peters, R., Yasar, S., Anderson, C. S., Andrews, S., Antikainen, R., Arima, H., Beckett, N., Beer, J. C., Bertens, A. S., Booth, A., van Boxtel, M., Brayne, C., Brodaty, H., Carlson, M. C., Chalmers, J., Corrada, M., DeKosky, S., Derby, C., Dixon, R. A., . . . Anstey, K. J. (2020). An investigation of antihypertensive class, dementia, and cognitive decline : A meta-analysis. Neurology, 94(3), e267-e281. https://doi.org/10.1212/WNL.0000000000008732
JYU-tekijät tai -toimittajat
Julkaisun tiedot
Julkaisun kaikki tekijät tai toimittajat: Peters, Ruth; Yasar, Sevil; Anderson, Craig S.; Andrews, Shea; Antikainen, Riitta; Arima, Hisatomi; Beckett, Nigel; Beer, Joanne C.; Bertens, Anne Suzanne; Booth, Andrew; et al.
Lehti tai sarja: Neurology
ISSN: 0028-3878
eISSN: 1526-632X
Julkaisuvuosi: 2020
Volyymi: 94
Lehden numero: 3
Artikkelin sivunumerot: e267-e281
Kustantaja: American Academy of Neurology
Julkaisumaa: Yhdysvallat (USA)
Julkaisun kieli: englanti
DOI: https://doi.org/10.1212/WNL.0000000000008732
Julkaisun avoin saatavuus: Ei avoin
Julkaisukanavan avoin saatavuus:
Julkaisu on rinnakkaistallennettu (JYX): https://jyx.jyu.fi/handle/123456789/68396
Tiivistelmä
High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimizing cognition. Our objective was to determine whether any particular antihypertensive class was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original participant data.
METHODS:
To identify suitable studies, MEDLINE, Embase, and PsycINFO and preexisting study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data sharing and collaboration. Outcome measures were incident dementia or incident cognitive decline (classified using the reliable change index method). Data were separated into mid and late-life (>65 years) and each antihypertensive class was compared to no treatment and to treatment with other antihypertensives. Meta-analysis was used to synthesize data.
RESULTS:
Over 50,000 participants from 27 studies were included. Among those aged >65 years, with the exception of diuretics, we found no relationship by class with incident cognitive decline or dementia. Diuretic use was suggestive of benefit in some analyses but results were not consistent across follow-up time, comparator group, and outcome. Limited data precluded meaningful analyses in those ≤65 years of age.
CONCLUSION:
Our findings, drawn from the current evidence base, support clinical freedom in the selection of antihypertensive regimens to achieve blood pressure goals.
YSO-asiasanat: kohonnut verenpaine; hoitomenetelmät; dementia; meta-analyysi
Liittyvät organisaatiot
OKM-raportointi: Kyllä
Raportointivuosi: 2020
JUFO-taso: 3
